PLA.sub.2 inhibitors and their use for inhibition of intestinal cholesterol absorption
AssigneeWarner-Lambert Company
InventorReynold Homan
Life of this patent
Estimating the term…
Abstract
Certain compounds have been synthesized and found to be effective inhibitors of phospholipase A.sub.2 (PLA.sub.2), and thereby useful in the treatment of intestinal cholesterol absorption and the disease states arising therefrom, such as hypercholesterolemia and coronary artery disease.
Claims5
A method of treating atherosclerosis or coronary artery disease in a mammal suffering therefrom which comprises administering to said mammal an effective amount of a compound of the formula ##STR17## wherein R and R.sub.1 are independently hydrogen, hydroxy, lower alkyl, halogen, trifluoromethyl, cyano, nitro, methylthio, lower alkenyl or lower alkynyl or a pharmaceutically acceptable salt thereof.
A method for blocking intestinal cholesterol absorption in an animal comprising administering to an animal in need of treatment a therapeutically effective amount of a pancreatic phospholipase A.sub.2 inhibitor of the formula ##STR18## wherein R and R.sub.1 are independently hydrogen, hydroxy, lower alkyl, halogen, trifluoromethyl, cyano, nitro, methylthio, lower alkenyl or lower alkynyl or a pharmaceutically acceptable salt thereof.
A method for reducing blood cholesterol levels in hypercholesterolemic subjects comprising administering to a subject in need of treatment a therapeutically effective amount of a pancreatic phospholipase A.sub.2 inhibitor of the formula ##STR19## wherein R and R.sub.1 are independently hydrogen, hydroxy, lower alkyl, halogen, trifluoromethyl, cyano, nitro, methylthio, lower alkenyl or lower alkynyl or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.